Ken Griffin’s Elevation Oncology ELEV Stock Holding History

Ken Griffin’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-355,203	Closed	-$130K	–	13063
2025 Q2	$130K	Buy	+355,203	New	+$119K	﹤0.01%	11090
2025 Q1	–	Sell	-266,243	Closed	-$152K	–	14719
2024 Q4	$150K	Buy	+266,243	New	+$157K	﹤0.01%	10885
2024 Q3	–	Sell	-40,113	Closed	-$59.5K	–	14450
2024 Q2	$108K	Sell	40,113 -1,529,451	-97%	-$5.76M	﹤0.01%	10809
2024 Q1	$8.05M	Buy	1,569,564 +978,081	+165%	+$3.17M	﹤0.01%	3229
2023 Q4	$318K	Sell	591,483 -248,718	-30%	-$132K	﹤0.01%	9051
2023 Q3	$557K	Buy	840,201 +1,607	+0.2%	+$1.63K	﹤0.01%	7828
2023 Q2	$1.27M	Buy	+838,594	New	+$2.21M	﹤0.01%	5958
2022 Q1	–	Sell	-21,856	Closed	-$132K	–	13811
2021 Q4	$132K	Buy	+21,856	New	+$151K	﹤0.01%	12426

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ken Griffin's ELEV Position: Q3 2025 in Review

Ken Griffin sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 355,203 shares — an estimated $130K sold.

Ken Griffin first reported a position in ELEV in Q4 2021 and held it in 8 quarters. The position peaked at $8.05M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Ken Griffin reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Ken Griffin sold 355,203 Elevation Oncology shares in Q3 2025, an estimated $130K.
Ken Griffin first reported a position in Elevation Oncology in Q4 2021 and held it in 8 quarters.
Ken Griffin's Elevation Oncology position peaked at $8.05M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.